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Loss-of-Function Mutation in the
Dioxygenase-Encoding FTO Gene Causes Severe
Growth Retardation and Multiple Malformations
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FTO is a nuclear protein belonging to the AlkB-related non-haem iron- and 2-oxoglutarate-dependent dioxygenase family. Although
polymorphisms within the ﬁrst intron of the FTO gene have been associated with obesity, the physiological role of FTO remains
unknown. Here we show that a R316Q mutation, inactivating FTO enzymatic activity, is responsible for an autosomal-recessive lethal
syndrome. Cultured skin ﬁbroblasts from affected subjects showed impaired proliferation and accelerated senescence. These ﬁndings
indicate that FTO is essential for normal development of the central nervous and cardiovascular systems in human and establish that
a mutation in a human member of the AlkB-related dioxygenase family results in a severe polymalformation syndrome.Ftowas originally identiﬁed in mice as one of the genes en-
coded by the 1.6 Mb deletion causing the fused toes (Ft)
mutant, an autosomal-dominant mouse mutation gener-
ated by a transgene integration into region D of mouse
Chr 8.1 In addition to Fto, the deleted segment also
contains three members of the Iroquois gene family (Irx3,
Irx5, and Irx6, also known as the IrxB complex) as well as
the Fts/Aktip and Ftm/Rpgrip1l genes. Mice heterozygous
for the Ft mutation are characterized by partial syndactyly
of forelimbs and thymic hyperplasia.1 Ft/Ft embryos die in
midgestation and present many abnormalities including
limb polydactyly and distal truncations, major brain and
heart defects, delay or absence of neural tube closure,
and facial structure hypoplasia.2,3
Interestingly, a human genome-wide search for type 2
diabetes susceptibility genes identiﬁed the strong associa-
tion of a series of single nucleotide polymorphisms
(SNPs), in tight linkage disequilibrium with rs9939609
and located in the ﬁrst intron of the FTO gene (MIM
610966), with higher body mass index (BMI) and obesity
risk in European cohorts.4,5 This association was replicated
in various European cohorts and several studies have been
performed trying to identify association between the
obesity risk allele and energy intake/expenditure or eating
behavior trait.6–8 However, how FTO variants modulate
components of the energy balance remains elusive so far.
FTO has been recognized as a member of the AlkB-related
family of non-haem iron- and 2-oxoglutarate-dependent
dioxygenases.9 These non-heme iron enzymes, which
require Fe2þ as a cofactor and 2-oxoglutarate and dioxygen
as cosubstrates, reverse alkylated DNA and RNA damages106 The American Journal of Human Genetics 85, 106–111, July 10,by oxidative demethylation.10–14 Fto-deﬁcient mice have
been recently described.15 Homozygous mutant mice are
viable but postnatal death occurs frequently and loss of
Fto leads to postnatal growth retardation, signiﬁcant
reduction in adipose tissue, and lean body mass.
We ascertained a large Palestinian Arab consanguineous
multiplex family in which nine affected individuals pre-
sented with a previously unreported polymalformation
syndrome (Figure 1A). The study was approved by the
supreme Israeli Helsinki Review Board (33/07-08) and
informed consent was obtained from all family members.
All affected individuals had postnatal growth retardation,
microcephaly, severe psychomotor delay, functional brain
deﬁcits, and characteristic facial dysmorphism. In some
patients, structural brain malformations, cardiac defects,
genital anomalies, and cleft palate were also observed
(Table 1). Early lethality resulting from intercurrent infec-
tion or unidentiﬁed cause occurred at 1–30 months of age.
Extensive biochemical, metabolic, and genetic analyses
failed to diagnose any previously known inherited disor-
ders. Because the pedigree suggested an autosomal-reces-
sive mode of inheritance, we performed a genome-wide
autozygosity screen with the Perkin Elmer Biosystems
linkage mapping set (version 1) and identiﬁed a unique
region of shared homozygosity on chromosome 16q12
(Figure S1 available online). Further genotype and haplo-
type analyses reduced the critical region to a 6.5Mb interval
between loci D16S411 and D16S3140 (maximum LOD
score Zmax¼ 4.16 at q¼ 0 at theD16S3136 locus). No other
genomic region showed consistent linkage. This genetic
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Figure 1. Genetic Analysis of a Family with Ante- and Postnatal Growth Retardation and a Severe Polymalformative Syndrome
(A) Pedigree of the family. Filled symbols and slashes indicate affected and deceased infants.
(B) Electrophoregrams showing the variation of FTO gene sequence in an affected infant and a healthy control.
(C) Part of the multiple sequence alignment of FTO representative orthologs (H.s, Homo sapiens; Ma.m,Macaca mulatta; R.n, Rattus nor-
vegicus; Mu.m,Mus musculus; C.f, Canis familiaris; E.c, Equus caballus; Or.a, Ornithorhynchus anatinus; Ov.a, Ovis aries; B.t, Bos taurus; M.d,
Monodelphis domestica; G.g, Gallus gallus; D.r, Danio rerio; X.t, Xenopus tropicalis; ABH2 H.s, human ABH2; ABH3 H.s, Human ABH3; AlkB
E.c, E. coli AlkB). The conserved residues are highlighted and the amino acid highlighted in red is the absolutely conserved arginine
involved in the R316Q mutation in patients (Ai, affected infant). Blue strands labeled with roman numerals identify three of the eight
b strands that form the conserved double-stranded b-helix of the 2OG-oxygenases.analyzed at both DNA and/or RNA levels (Table S1). We
identiﬁed a homozygous single-nucleotide variation at
cDNA position 947 (c.947G/A) within the FTO gene
(Figure 1B). The c.947G/A transition predicts a p.R316Q
substitution. Notably, this amino acid residue is absolutely
conserved across all known FTO paralogs and AlkB ortho-
logs (Figure 1C) and is involved in 2-oxoglutarate coordina-
tion by forming stabilizing salt bridges with the carboxyl-
ates of this cosubstrate.9 This variant cosegregated with
thedisease andwasnot found in730control chromosomes,
including 378 chromosomes from individuals of Palesti-
nian Arab origin. We subsequently undertook to estimate
the frequency of FTO sequence variants within the general
population. FTO coding exons and intron-exon boundaries
sequence was determined in 1492 controls of European
descent without overt disease or syndromic features. No
nonsense variant was identiﬁed and the prevalence of
missense variants was 0.87%. In addition, neither homozy-
gousmissensemutationnor compositeheterozygousmuta-
tions were detected in this large series of control subjects
(data not shown), further supporting the hypothesis that
the R316Q mutation is the disease-causing defect. To esti-
mate the prevalence of FTO mutations, 27 unrelated chil-The Amdrenwith partially overlapping clinical features were tested
but no mutation in the FTO gene was identiﬁed, strength-
ening the idea that the new syndrome described here is
a very rare condition.
FTO belongs to the AlkB-related protein family and was
shown to localize in the nucleus.9 Immunoﬂuorescence
experiments performed on patient and control ﬁbroblasts
demonstrated that the mutation did not affect its nuclear
localization (data not shown). Murine and human Fto
have been shown to demethylate 3-methylthymine and
3-methyluracil residues in single-stranded DNA and RNA
in vitro, albeit with a relatively low efﬁciency. Fto was less
active on themore common forms ofmethylatedDNAbase
damage, 1-methyladenine and 3-methylcytosine.9–14,16
Moreover, the recombinant murine Fto protein mutated
in the residue corresponding to human R316 amino acid
displays a much reduced or absent DNA demethylation
activity. To investigate the functional consequences of the
R316Q mutation, we tested the catalytic activity of the
wild-type and mutant R316Q FTO proteins in vitro. Two
different assays were used: the ﬁrst followed the conversion
of the cosubstrate 2-oxoglutarate to succinate and the
second monitored the ability of FTO to demethylateerican Journal of Human Genetics 85, 106–111, July 10, 2009 107
Table 1. Major Clinical Features in Affected Individuals with
c.947G/A Mutation in FTO
Clinical Features
Number of Patients Presenting
the Symptom/Number
of Patients Examined
Survival
Death before 3 years of age 8/8
Build
Intrauterine growth retardation 3/7
Failure to thrive (severe) 8/8
CNS
Developmental delay (severe) 8/8
Postnatal microcephaly (severe) 8/8
Hypertonicity 6/6
Hydrocephalus 4/8
Lissencephaly 3/8
Seizures 3/8
Dandy walker malformation 2/8
Brain atrophy 1/8
Heart
Ventricular septal defect,
atrio ventricular defect,
atent ductus arteriosus
6/8
Hypertrophic cardiomopathy 4/8
Dysmorphism
Ante verted nostrils 7/7
Thin vermilion 7/7
Prominent alveolar ridge 6/6
Retrognathia 7/7
Coarse face 7/7
Protruding tongue 3/7
Other
Short neck 7/7
Cutis marmorata 7/7
Drumstick ﬁngers 6/6
Brachydactyly 6/6
Toenail hypoplasia 6/6
Skull asymmetry 6/6
Neuro sensory deafness 5/5
Weak cry 4/6
Umbilical hernia 4/6
Hypertrophy of labia/genital
ambiguity/undescending testis
4/7
Cleft palate/Biﬁd uvula 3/6
Optic disk abnormality 3/7
Medical information was available from 8/9 patients.108 The American Journal of Human Genetics 85, 106–111, July 10,3-methylthymine in DNA. Most 2-oxoglutarate- and Fe2þ-
dependent dioxygenases slowly catalyze the conversion of
2-oxoglutarate to succinate even in the absence of their
prime substrate,16 and this uncoupled reaction may be
stimulated by substrates or their analogs. We optimized
conditions to assay the ability of human recombinant
FTOprotein to convert 14C-2-oxoglutarate to 14C-succinate
and found that this activity was stimulated 6- to 8- fold by
free 3-methylthymidine (Figure 2A). Other nucleosides
such as 1-methyldeoxyadenosine and thymidine or the
base 3-methylthymine did not stimulate the activity (data
not shown). Interestingly, the R316Q FTO mutant protein
hadnodetectable ability to catalyze theuncoupled reaction
and also was not stimulated by 3-methylthymidine
(Figure 2A). The ability of FTO to demethylate 14C-labeled
3-methylthymine in single-stranded poly(dT) substrate
was assayed bymeasuring the release of 14C-formaldehyde.
The optimum pH for the demethylation of 3-methylthy-
mine in DNA by AlkB, ABH2 (MIM 610602), and ABH3
(MIM 610603) is 6 to 6.5 and this is also the case for human
FTO. Wild-type FTO11,16,17 actively but slowly demethy-
lated this substrate whereas the mutant R316Q protein
was inactive in the assay (Figure 2B). The defective activity
of FTO, as observed in both assays, is most likely due to
the inability of the mutant protein to interact with the
cosubstrate 2-oxoglutarate.
To gain insight into the function of the FTO gene product
and the pathophysiology of the disease, we investigated the
expression of FTO in human embryos and adult tissues.
RT-PCR showed an ubiquitous expression in all fetal and
adult tissues tested, as has been observed in mice (data not
shown).18 Human embryo sections were hybridized in situ
at stages Carnegie (C)15, 33–36 days postfertilization (dpf)
and C18 (44–46 dpf) with antisense probes against FTO
and sense probes as negative controls.We observed a nearly
ubiquitous expressionof FTO, withhigher expression in the
central nervous systemand the liver. In the heart, themitral
and semilunar valves and the wall of the pulmonary trunk
stained as did the ventricular myocardium, and a strong
and uniform expression was observed in the developing
pituitary and the frontonasal andmandibularmesenchyme
(Figure S2). It is worth noting that this wide spatiotemporal
pattern of expression is consistent with the broad spectrum
of clinical manifestations of the disease (Table 1).
Interestingly, the cultured skin ﬁbroblasts of patient
III.15 displayed an altered morphology (including hyper-
trophy), an increased number of vacuoles and cellular
debris (Figure 3A), a reduced life span, and decreased prolif-
erative abilities when compared to controls (Figure 3B).
Cellular expression of the senescence-associated b-galacto-
sidase (SA-b-Gal) is thought to be a reliable indicator of
the switch mechanism that occurs when cells enter the
senescent phenotype.19 Notably, a signiﬁcantly elevated
number of SA-b-Gal-positive cells, increasing with passage
numbers, was found in patient cultured cells compared to
passage-matched control ﬁbroblasts (Figure 3C). Although
further analyses on skin ﬁbroblasts of additional patients2009
A B Figure 2. Biochemical Analyses of the Wild-Type
and Mutant FTO Proteins
(A) Puriﬁed FTO was added to 10 ml reaction mixture
containing 50 mM HEPES.KOH (pH 7), 50 mg/ml
BSA, 4 mM ascorbate, 75 mM Fe(NH4)2(SO4)2, and
20 mM [5-14C]-2-oxoglutarate (30 mCi/mmol from
Moravek Biochemicals) and incubated at 37C for
various times. To measure stimulation of this activity
by 3-methylthymidine, 1 mM 3-methylthymidine
(Moravek Biochemicals) was included in the assay
mix. The reaction was stopped by adding 5 ml stop
solution containing 20 mM succinate, 20 mM 2-oxo-
glutarate followed by 5 ml 160 mM dinitrophenylhy-
drazine, which precipitates 2-oxoglutarate. This mix
was incubated at room temperature for 30 min. An
additional 10 ml 1M 2-oxoglutarate was added and
incubated for a further 30 min. The precipitate was removed by centrifugation. Clear supernatant (10 ml) was scintillation counted to
monitor the 14C-succinate generated. Time course of activity of 1.5 mM FTO: open and closed squares, wild-type FTO protein; open
and closed triangles, mutant R316Q FTO protein. Open symbols and dotted line: without 3-methylthymidine; closed symbols and solid
line: with 3-methylthymidine (1 mM).
(B) A DNA substrate containing 14C-3-methylthymine was prepared by treating poly(dT) with [14C]-methyl iodide (54 Ci/mmole, Amer-
sham Biosciences) as previously described11 and had a speciﬁc activity of 1580 cpm/mg poly(dT). FTO was added to the 14C-methylated
poly(dT) substrate (1000 cpm) in a 100 ml reaction mix containing 50 mM MES-HCl (pH 6), 75 mM Fe(NH4)2(SO4)2, 100 mM 2-oxoglu-
tarate, 2 mM ascorbate, 10 mg/ml bovine serum albumin and incubated at 20C for various times. All assays were performed in triplicate.
To stop the reaction, EDTA was added to a ﬁnal concentration of 10 mM. The polynucleotide substrate was then ethanol precipitated in
the presence of carrier calf thymus DNA. Two-thirds of the ethanol-soluble radioactivematerial wasmonitored by scintillation counting.
Equal volumes of the protein preparations were assayed. Standard error of the mean is shown for each time point. Closed square, 2 mM
wild-type FTO protein; closed triangle, 2 mMmutant R316Q FTO protein; open circle, ‘‘mock prep’’ prepared in the absence of recombi-
nant FTO expression. Equal volumes of the protein preparations were also examined by SDS-10% PAGE.are necessary to validate these ﬁndings, taken together
these data could yet suggest that the defective FTO activity
may cause premature senescence-like phenotype.
Although repair of alkylated nucleic acid by oxidative
demethylation is crucial to maintain genome integrity, no
AlkB-related protein mutations have been hitherto identi-
ﬁed in human. The results reported here provide therefore
the ﬁrst example of a human disorder related to the defect
of an AlkB-related protein. The Escherichia coli AlkB protein
catalyzes the oxidative demethylation of 1-methyladenine,
3-methylcytosine, and 3-methylthymine inDNA and RNA.
Eight mammalian orthologs of AlkB have been previously
identiﬁed (ABH1 to 8),20 and FTO is the ninth member
of this family. Of this family, only ABH2 and ABH3 have
been demonstrated to be highly active in repairingmethyl-
ation damage to DNA.13,14 In comparison, ABH1 (MIM
605345) has a modest activity on 3-methylcytosine in
single-stranded DNA or RNA21 whereas FTO has a similar
low activity on 3-methylthymine in these substrates.9,16
Mice lacking either Abh2 or Abh3 have no overt phenotype
but the Abh2/ mice accumulate signiﬁcant levels of
1-methyladenine in their genomes.22 Notably, Abh1/
mice are viable but have intrauterine growth retardation
and defects in placental differentiation.23
Surprisingly, although homozygous Fto/ mice have
postnatal growth retardation, signiﬁcant reduction in
adipose tissue, and lean body mass, they are not, however,
reported to have any developmental abnormalities in the
central nervous or cardiovascular systems.15 Thus, humans
homozygous for a catalytically inactive FTO and Fto null
mice share the growth retardation phenotype but both
mutations differ in the impact on development of centralThe Amnervous and cardiovascular systems. There are several
possible reasons for the different ﬁndings in our patients
versus the Fto/ mouse. First, major phenotypic differ-
ences between rodent models and humans harboring
identical mutations are well described. For example, matu-
rity-onset diabetes of the young subtype 3 (MODY3 [MIM
600496]) is caused by heterozygous mutations in the tran-
scription factor hepatocyte nuclear factor (HNF)-1a (MIM
142410).24 By contrast, mice with heterozygous mutations
in Hnf-1a gene are phenotypically normal.25 Second, it is
possible that the presence, in the nucleus, of a mutant
catalytically inactive FTO might have biochemical conse-
quences over and above that seenwith complete deﬁciency
of Fto. These could include toxic ‘‘gain-of-function’’ effects
or dominant-negative interference with other related
family members. Finally, it is formally possible that the
phenotype seen in the human subjects is due to a combina-
tion of the mutant FTO and a second, as yet undetected,
mutation in the 6Mb critical region. The fact that nomuta-
tions were detected on sequencing of the coding regions
and splice junctions of all 28 known and putative genes in
that linked region makes the chances of such a second
mutation very small.
A cluster of variants locatedwithin the ﬁrst intron of FTO
has recentlybeen strongly and reproducibly associatedwith
human adiposity.4,5 Yet, whether these variants inﬂuence
the risk of obesity directly, via the altered expression of
FTO or through other mechanisms, remains questionable.
In this regard, it is worth noting that homozygosity for
the R316QFTOmutation caused severe growth retardation.
Detailed anthropometric measurements are not available
on unaffected family members but, noticeably, none oferican Journal of Human Genetics 85, 106–111, July 10, 2009 109
the parents were clinically obese. Given the results from the
Fto-deﬁcient mice, it might be hypothesized that humans
heterozygous for a loss-of-functionmutation in FTOmight
actually be relatively resistant to becoming obese. Future
studies of the body composition of carrier and
noncarrier relatives will be required to clarify the relation-
ship between FTO variant heterozygosity and adiposity.
The molecular mechanisms whereby the mutant FTO
leads to the severe phenotype observed in our patients
remain unknown. The fact that (1) FTO is a member of
the Alk-B-related family of dioxygenases, (2) at least two
of themammalianmembers of this family have established
roles inDNA repair, and (3) FTO candemethylate 3-methyl-
thymine in the context of DNA might suggest that FTO
plays a role in the maintenance of genome integrity. If
that were the case, one could easily understand how FTO
defect relates to developmental malformations and the
accelerated senescence observed in cultured ﬁbroblasts
derived from the patients. However, it should also be
pointed out that (1) several members of the mammalian
Alk-B-related family have no established role inDNA repair,
(2) FTO demethylates 3-methylthymine slowly and inefﬁ-
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Figure 3. Cell Morphology and Proliferative Abili-
ties of Cultured Skin Fibroblasts Harboring the
R316Q FTO Mutation
(A) Fibroblast morphology. The arrow shows altered
cell morphology and enlarged cell size of a patient
ﬁbroblast.
(B) Fibroblast growth curves. Fibroblasts were seeded
at a density of 5000 cells/well in 12-well dishes. The
number of cells per dish was determined with
a CASY cell counter on days 2, 5, 7, 9, and 11 after
seeding. Filled and open symbols correspond to
patient and control ﬁbroblasts, respectively. Data
correspond to the mean of three replicates. Standard
error of the mean is shown for each point.
(C) Senescence-associated b-galactosidase assay.
Fibroblasts were seeded on 6-well dishes at a density
of 130,000 cells/well. Senescent ﬁbroblasts were
stainedwith the Senescence b-Galactosidase Staining
Kit (Cell Signaling Technology). Percentages of
b-galactosidase-positive cells for passages 7, 9, and 13
were calculated on the basis of approximately 100
cells. Data correspond to themeanof three replicates.
Standard error of the mean is shown for each point.
ciently, suggesting that this is not its true phys-
iological substrate, (3) 3-methylthymine is a
very rare lesion in vivo, and (4) defective repair
of rare methylated bases in DNA can hardly be
related to the striking increase in energy expen-
diture observed in Fto-deﬁcient mice. Taken
together, this suggests that FTO roles in the
nucleus are presumably not restricted to DNA
repair.
Because of its association with obesity, FTO is
currently the subject of intense interest. The
ﬁnding of obesity resistance in Fto-deﬁcient
mice has led to the suggestion that interference
with Fto enzymatic function might be a novel and inter-
esting antiobesity therapeutic strategy. The discovery that
humans homozygous for an enzymatically inactive mutant
formofFTOhavemultiple congenital abnormalities suggests
that any program of research exploring the therapeutic
utility of FTO inhibitors should incorporate a particularly
careful assessment of teratogenicity and other toxic effects.
Supplemental Data
Supplemental data include two ﬁgures and one table and can be
found with this article online at http://www.ajhg.org/.
Acknowledgments
Wearegrateful to thepatients for theirparticipation in the study.We
acknowledge Jean Philippe Jais for LOD score calculation, Carron
Sher for participation to clinical evaluation, Uli Ru¨ther for kindly
providing FTO antibodies, Ce´line Cluzeau for help with western
blotting, Peter Robins for puriﬁcation of FTO protein, andMarcella
Ma and Debbie Lyon for additional technical assistance. This study
was supported by the Centre National de la Recherche Scientiﬁque,
the Agence Nationale de la Recherche, the Re´gion Ile-de-France, EU110 The American Journal of Human Genetics 85, 106–111, July 10, 2009
FP6 EUGENE2 (LSHM-CT-2004-512013), EC FP6 Marie Curie, the
Medical Research Council UK, Cancer Research UK, the Wellcome
Trust, and NIHR Cambridge Biomedical Research Centre.
Received: April 27, 2009
Revised: May 29, 2009
Accepted: June 2, 2009
Published online: June 25, 2009
Web Resources
The URLs for data presented herein are as follows:
Ensembl Genome Browser, http://www.ensembl.org/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/
National Center for Biotechnology Information, http://www.ncbi.
nlm.nih.gov/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/
References
1. Peters, T., Ausmeier, K., and Ruther, U. (1999). Cloning of
Fatso (Fto), a novel gene deleted by the Fused toes (Ft) mouse
mutation. Mamm. Genome 10, 983–986.
2. Gotz, K., Briscoe, J., and Ruther, U. (2005). Homozygous Ft
embryos are affected in ﬂoor plate maintenance and ventral
neural tube patterning. Dev. Dyn. 233, 623–630.
3. Anselme, I., Laclef, C., Lanaud, M., Ruther, U., and Schneider-
Maunoury, S. (2007). Defects in brain patterning and head
morphogenesis in the mouse mutant Fused toes. Dev. Biol.
304, 208–220.
4. Frayling, T.M., Timpson, N.J., Weedon, M.N., Zeggini, E.,
Freathy, R.M., Lindgren, C.M., Perry, J.R., Elliott, K.S., Lango,
H., Rayner, N.W., et al. (2007). A common variant in the FTO
gene is associated with body mass index and predisposes to
childhood and adult obesity. Science 316, 889–894.
5. Dina, C., Meyre, D., Gallina, S., Durand, E., Korner, A., Jacob-
son, P., Carlsson, L.M., Kiess, W., Vatin, V., Lecoeur, C., et al.
(2007). Variation in FTO contributes to childhood obesity
and severe adult obesity. Nat. Genet. 39, 724–726.
6. Speakman, J.R., Rance, K.A., and Johnstone, A.M. (2008).
Polymorphisms of the FTO gene are associated with variation
in energy intake, but not energy expenditure. Obesity (Silver
Spring) 16, 1961–1965.
7. Haupt, A., Thamer, C., Staiger, H., Tschritter, O., Kirchhoff, K.,
Machicao, F., Haring, H.U., Stefan, N., and Fritsche, A. (2009).
Variation in theFTOgene inﬂuences food intakebutnot energy
expenditure. Exp. Clin. Endocrinol. Diabetes 117, 194–197.
8. Cecil, J.E., Tavendale, R., Watt, P., Hetherington, M.M., and
Palmer, C.N. (2008). An obesity-associated FTO gene variant
and increased energy intake in children. N. Engl. J. Med. 359,
2558–2566.
9. Gerken, T., Girard, C.A., Tung, Y.C., Webby, C.J., Saudek, V.,
Hewitson, K.S., Yeo, G.S., McDonough, M.A., Cunliffe, S.,
McNeill, L.A., et al. (2007). The obesity-associated FTO gene
encodes a 2-oxoglutarate-dependent nucleic acid demethy-
lase. Science 318, 1469–1472.
10. Trewick, S.C., Henshaw, T.F., Hausinger, R.P., Lindahl, T., and
Sedgwick, B. (2002). Oxidative demethylation by Escherichia
coli AlkB directly reverts DNA base damage. Nature 419,
174–178.The Am11. Koivisto, P., Robins, P., Lindahl, T., and Sedgwick, B. (2004).
Demethylation of 3-methylthymine in DNA by bacterial and
human DNA dioxygenases. J. Biol. Chem. 279, 40470–40474.
12. Falnes, P.O., Johansen, R.F., and Seeberg, E. (2002). AlkB-medi-
ated oxidative demethylation reverses DNA damage in Escher-
ichia coli. Nature 419, 178–182.
13. Duncan, T., Trewick, S.C., Koivisto, P., Bates, P.A., Lindahl, T.,
and Sedgwick, B. (2002). Reversal of DNA alkylation damage
by two human dioxygenases. Proc. Natl. Acad. Sci. USA 99,
16660–16665.
14. Aas, P.A., Otterlei, M., Falnes, P.O., Vagbo, C.B., Skorpen, F.,
Akbari, M., Sundheim, O., Bjoras, M., Slupphaug, G., Seeberg,
E., et al. (2003). Human and bacterial oxidative demethylases
repair alkylation damage in both RNA and DNA. Nature 421,
859–863.
15. Fischer, J., Koch, L., Emmerling, C., Vierkotten, J., Peters, T.,
Bruning, J.C., and Ruther, U. (2009). Inactivation of the Fto
gene protects from obesity. Nature 458, 894–898.
16. Jia, G., Yang, C.G., Yang, S., Jian, X., Yi, C., Zhou, Z., and He,
C. (2008). Oxidative demethylation of 3-methylthymine and
3-methyluracil in single-stranded DNA and RNA by mouse
and human FTO. FEBS Lett. 582, 3313–3319.
17. Kaule, G., and Gunzler, V. (1990). Assay for 2-oxoglutarate
decarboxylating enzymes based on the determination of
[1–14C]succinate: Application to prolyl 4-hydroxylase. Anal.
Biochem. 184, 291–297.
18. Stratigopoulos, G., Padilla, S.L., LeDuc, C.A., Watson, E., Hat-
tersley, A.T., McCarthy, M.I., Zeltser, L.M., Chung, W.K., and
Leibel, R.L. (2008). Regulation of Fto/Ftm gene expression in
mice and humans. Am. J. Physiol. Regul. Integr. Comp. Phys-
iol. 294, R1185–R1196.
19. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley,
C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O.,
et al. (1995). A biomarker that identiﬁes senescent human
cells in culture and in aging skin in vivo. Proc. Natl. Acad.
Sci. USA 92, 9363–9367.
20. Kurowski, M.A., Bhagwat, A.S., Papaj, G., and Bujnicki, J.M.
(2003). Phylogenomic identiﬁcationofﬁvenewhumanhomo-
logs of the DNA repair enzyme AlkB. BMC Genomics 4, 48.
21. Westbye, M.P., Feyzi, E., Aas, P.A., Vagbo, C.B., Talstad, V.A.,
Kavli, B., Hagen, L., Sundheim, O., Akbari, M., Liabakk, N.B.,
et al. (2008). Human AlkB homolog 1 is a mitochondrial
protein that demethylates 3-methylcytosine in DNA and
RNA. J. Biol. Chem. 283, 25046–25056.
22. Ringvoll, J., Nordstrand, L.M., Vagbo, C.B., Talstad, V., Reite,
K., Aas, P.A., Lauritzen, K.H., Liabakk, N.B., Bjork, A., Doughty,
R.W., et al. (2006). Repair deﬁcient mice reveal mABH2 as the
primary oxidative demethylase for repairing 1meA and 3meC
lesions in DNA. EMBO J. 25, 2189–2198.
23. Pan, Z., Sikandar, S., Witherspoon, M., Dizon, D., Nguyen, T.,
Benirschke, K., Wiley, C., Vrana, P., and Lipkin, S.M. (2008).
Impaired placental trophoblast lineage differentiation in
Alkbh1(/) mice. Dev. Dyn. 237, 316–327.
24. Yamagata, K., Oda, N., Kaisaki, P.J., Menzel, S., Furuta, H., Vax-
illaire, M., Southam, L., Cox, R.D., Lathrop, G.M., Boriraj, V.V.,
et al. (1996). Mutations in the hepatocyte nuclear factor-
1alpha gene in maturity-onset diabetes of the young
(MODY3). Nature 384, 455–458.
25. Pontoglio, M., Barra, J., Hadchouel, M., Doyen, A., Kress, C.,
Bach, J.P., Babinet,C., andYaniv,M. (1996).Hepatocytenuclear
factor 1 inactivation results in hepatic dysfunction, phenylke-
tonuria, and renal Fanconi syndrome. Cell 84, 575–585.erican Journal of Human Genetics 85, 106–111, July 10, 2009 111
